Have non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord stromal tumors)
Patients with unbiopsied diffuse intrinsic pontine tumors will NOT be eligible for this study.
For patients with CNS tumors, any baseline neurologic deficit, including seizures, must be stable for at least one week prior to initiating study treatment
Part A: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors
Clinical T tumors
Tumors must have PD-L status tested centrally as part of the ALCHEMIST-SCREEN protocol
Patients with grade  NRSTS tumors of any size are not eligible
Patients with MYCN amplified tumors are not eligible
Patients must have had all grossly visible papillary tumors removed within  days prior to registration or cystoscopy confirming no grossly visible papillary tumors within  days prior to registration
Ewing's family of tumors (EFTs)
Brain Tumors
Rare Tumors:
COHORT A: Patients with newly diagnosed, previously untreated primary tumors that present with brain metastases should not forego available therapy that has demonstrated a definitive overall survival benefit as first line therapy for metastatic disease; therefore, in cases of previously untreated systemic solid tumors only those patients for whom there is no available therapy with definitive overall survival benefit, those that have failed at least one line of prior therapy for their primary tumor, or those refusing standard therapy will be eligible for this study; specifically, for patients with previously untreated primary tumors, the following diagnoses will be excluded: HER-positive breast cancer; small cell lung cancer; non-small cell lung carcinoma (NSCLC) with targetable genomic tumor aberrations (e.g. EGFR, ALK)
Carcinoid tumors of any site are eligible; patients with pancreatic neuroendocrine tumors are excluded
Patients with histologically or serologically confirmed relapsed/refractory nonseminoma germ cell tumor, (i.e., embryonal carcinoma, choriocarcinoma, or yolk sac tumors) including female germ cell tumors (GCT) and primary mediastinal NSGCT
Subjects with any of the following tumors who have experienced relapse following front-line therapy, or who are refractory to front-line therapy, and subjects with tumors that carry a poor prognosis and have no known standard curative therapy are eligible;\r\n* Brain tumors of all World Health Organization (WHO) grades except diffuse intrinsic pontine glioma (DIPG); patients with DIPG are not eligible\r\n* Extracranial solid tumors including histiocytoses (e.g. Langerhans cell histiocytosis [LCH], juvenile xanthogranuloma [JXG], histiocytic sarcoma)
Subjects must have measurable disease by RECIST . criteria including one target tumor for injection. Superficial tumors must have one tumor greater than or equal to . cm, deep tumors greater than or equal to . cm (as measured by caliper (for non-injected tumors only) or image guidance);
Subjects must have a minimum of one injectable lesion as determined by the investigator (for superficial tumors) or radiologist (deep tumors).
Tumors whose proximal end are higher that the level of the carina
Cumulative volume of all tumors ?  cc
Neuronal tumors \r\n* Ganglioglioma (excluding tumors with anaplastic astrocytic components) \r\n* Infantile desmoplastic ganglioglioma
Tumors of all locations in the central nervous system, with appropriate histology, are eligible for study; however, patients with intrinsic brainstem tumors of the pons will be excluded from the study; patients with primary spinal cord lesions are allowed; patients with metastatic disease are also allowed
Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded)
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
Gastroenteropancreatic neuroendocrine tumors (GEPNET).
High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden.
Epithelial tumors of low malignant potential, stromal tumors, and germ cell tumors of the ovary
INCLUSION CRITERIA FOR STRATUM C: Patients must have a histologically confirmed primary brain tumor that is recurrent, progressive or refractory; inclusion criteria encompasses all types of brain tumors (e.g. gliomas, embryonal tumors or any other type of brain tumor as long as other eligibility criteria are met;\r\n* Patients with high-grade gliomas are eligible for this clinical trial at least  weeks after completion of radiotherapy independent of tumor progression/recurrence as long as they are not enrolled on any other therapeutic clinical trial and there is macroscopic residual disease\r\n* Patients with other concomitant tumors associated with CMMRD syndrome including gastrointestinal polyps/adenomas and carcinomas, lymphomas and leukemias will be eligible as long as they are not requiring anticancer therapy directed against these other cancers and meet all other eligibility criteria
Patients with low grade gliomas and Rb negative tumors
Patients diagnosed with primary CNS tumors
Patients with sessile appearing tumors, which may be invasive or high-grade
In addition to having AR+ tumors, patients must fit into  of the  following categories:
PART I: Adults with malignant soft tissue and bone tumors and recurrent or progressive, metastatic solid tumors who have progressed on standard therapies with known benefit but for whom anti-HER therapy is not clinically indicated:\r\n* Patients with ovarian, cervical, colon, gastric/gastroesophageal junction, non-small cell lung, renal cell, bladder, malignant soft tissue and bone tumor, prostate cancer or other solid tumors that is known to be HER +, + or + by immunohistochemistry (IHC) OR have a Vysis fluorescent in situ hybridization (FISH) result >= .\r\n* Patients with breast cancer that is known to be HER + or + by IHC or with a Vysis FISH result of . - < .
Both peripheral and central tumors are accepted for this trial
IO therapy resistant or insensitive tumors
Necrotic tumors or tumors close to large blood vessels that may impose an increased bleeding risk when treated with anti-VEGF agents.
Patients with primary CNS tumors are ineligible.
Infratentorial tumors
T to Ta tumors OR T tumors smaller than  cm invading the mediastinal or pericardial pleura are also eligible for this protocol as long as normal tissue dose constraints can be met
Phase a: Patients with various solid tumors or NHL who have received prior therapy.
Have Karnofsky score ? at enrollment (not applicable for subjects with benign bone tumors)
Phase : Participants must be diagnosed with histologically confirmed solid tumors (excluding CNS tumors), which is relapsed or refractory, and for which there are no currently available therapies.
Patients with rapidly progressing tumors, as judged by the investigator
Patients with secreting tumors must be receiving pharmacologic catecholamine blockade
T tumors with involvement of any adjacent structure, including the trachea, aorta or pleura
Patients with tumors that cannot be measured or clinically followed
Patients with tumors >  cm or tumors involving the main bronchus or associated vessels or tumors that invade any critical structures (such as esophagus, brachial plexus, heart, mediastinal major vessels) are not suitable for SABR
Patients with progression of multifocal tumors or tumors involving the posterior fossa (brainstem and cerebellum) will be excluded, as will patients where the anticipated treatment margin will be within  mm of critical intracranial structures (e.g., primary branches of cerebral vessels, dural sinuses, hypophysis or cranial nerves).
For subjects enrolled for major deformity or a significantly disfiguring tumor, eligible tumors will be limited to tumors of the head & neck or those on other areas of the body that are unable to be concealed by standard garments; in order to enroll a plexiform neurofibroma for these indications, the Study Chair or Co-Chair must be contacted to review patient eligibility prior to enrollment
Subjects with low grade tumors (histologic grade /)
Radiographic evidence of cavitary or necrotic tumors
Tumors must be potentially surgically resectable via a transoral approach, at the discretion of the treating surgeon
non-hilar tumors
Patients may have single or multinodular tumors
Has measurable disease based on either RECIST . for solid tumors or RANO for CNS tumors
Participants with preoperatively staged T, N, or N tumors who return >  weeks following completion of neoadjuvant chemoradiation therapy (CRT)
Severely symptomatic rectal tumors (near-completely obstructing, symptomatic bleeding)
Patients must have histologically confirmed advanced RCC (any histology); collecting duct tumors and tumors originating from the renal pelvis or upper urinary tract are considered of urothelial origin and are excluded from this protocol
Subjects must have measurable liver tumors that are suitable for injection.
Only MUC^ecto tumors with moderate to strong immunoreactive scores (-) will be considered positive
Patients whose tumors are positive for the sensitizing ROS- fusion
Patients whose tumors are deemed unresectable by clinical/imaging criteria
Recurrent pediatric brain tumors determined candidates for MLA as determined by the treating neurosurgeon
Patients must have untreated or relapsed SCCS that is considered to be aggressive and locally advanced by the following criteria: tumors  cm or more, tumors invading deep tissues such as muscle, cartilage or bone; tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes; patients may have had prior surgical interventions or been treated with investigational agents with residual or recurrent disease
Radiographic evidence of cavitary or necrotic tumors
Patients with primary tumors located at or above the carina
Surgery achieves either no gross residual disease or optimal cytoreductive status defined as no single lesion measuring more than  cm in its greatest diameter (this protocol calls for the intentional delay in resection of up to  tumors per patient until the HIPEC procedure is complete; the surgeon will identify these tumors as easily resectable from a technical and safety aspect)
Epithelial tumors of low malignant potential, stromal tumors, and germ cell tumors of the ovary
Patients with tumors primarily of the tail of the pancreas requiring a distal pancreaticoduodenectomy would be excluded; tumors of the body that require a surgical approach similar to pancreatic head tumors are acceptable
Infratentorial and multi-focal tumors are eligible
Patients must have a confirmed histopathologic diagnosis and be classified as high risk defined by having an expected survival of < %; examples include:\r\n* Neuroblastoma or ganglioneuroblastoma\r\n** Failure to achieve at least a partial response (PR) after induction therapy with Childrens Oncology Group (COG) ANBL or standard chemotherapy\r\n** Refractory to induction chemotherapy with COG ANBL or standard chemotherapy\r\n** Patients with high risk disease whose autologous peripheral blood stem cell product is contaminated with neuroblastoma or who do not have an autologous product available\r\n** Patients with high risk disease who do not meet eligibility requirements/organ function requirements for myeloablative conditioning\r\n** Patients with >=  identified lesions on the end of induction (COG ANBL or standard chemotherapy) meta-iodobenzylguanidine (MIBG) scan \r\n* Stage  rhabdomyosarcoma\r\n* Metastatic Ewing sarcoma\r\n* Osteosarcoma with metastatic disease beyond the lungs and/or with lung metastases not amenable to resection\r\n* Hepatoblastoma not amenable to resection\r\n* Metastatic melanoma\r\n* Desmoplastic small round cell tumor\r\n* Brain tumors such as astrocytic tumors, oligodendroglial tumors, ependymal tumors, choroid plexus tumors, other neuroepithelial tumors, neuronal and mixed neuronal-glial tumors, tumors of the pineal region, embryonic tumors\r\n* Any other solid tumor and soft tissue sarcoma with an estimated < % chance of survival will be considered on a case by case basis at the departmental tumor board and/or sarcoma meeting
Biliary strictures caused by confirmed benign tumors
For tumors that are invasive, HER must be performed (positive or negative is acceptable).
Patients with measurable inoperable, histologically confirmed primary lung and esophageal carcinomas, thymic neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas, as well as patients with gastric, colorectal or renal cancers and sarcomas metastatic to the thorax are eligible
Bulky disease patients - tumors encompassing >% of the liver volume and / or inferior vena cava invasion
WHO grade I: tumor that are newly diagnosed and tumors that are incompletely excised; tumors that have recurred post resection
Patients must have the diagnosis of (a) DSRCT with peritoneal involvement or (b) other H-positive solid tumors involving the peritoneum (e.g. adrenocortical carcinoma, Wilm's tumor)
For tumors other than DSRCT, H reactivity must be confirmed by immunohistochemistry
Pure sarcomas or borderline tumors or mucinous tumors
Group : NRAS or HRAS mutant solid tumors(Part B)
Patient with NRS (- scale) pain score ?  at the targeted tumors (i.e: both tumors targeted for treatment must have NRS ? ) irrespective of medication
Targeted (most painful) tumors:
More than  metastatic tumors
Tumors must be supratentorial in location.
Subjects must not have tumors adjacent to vital structures such as carotid arteries.
At least two BCC tumors, preferably more; these tumors must be located in different body regions or alternatively, located >  cm apart at sites that can be reproducibly separated into red and blue illumination fields
Patients with tumors that are not curable by salvage approaches including resection and/or re-irradiation.
Patients with non-melanoma skin cancers (NMSC) must have advanced or refractory tumors\r\n* Advanced/unresectable is defined by at least  of the following criteria: tumors  cm or more, tumors considered unresectable, tumors invading deep tissues such as muscle, cartilage or bone, tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes and/or distant sites\r\n* Refractory is defined by persistent or recurrent tumor despite prior therapy consisting of at least  of the following: surgery, radiation therapy, intralesional therapy, topical therapy, or systemic therapy
Multiple (? ) separate enhancing tumors
tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate
Tumors in which the invasive component is present only as micro-invasion
Patients with grade  non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) tumors of any size are not eligible
Assessment of GD status is not required for NB or for other tumors known to express GD in % or more of cases: specifically osteosarcoma (GD expressed in %), spindle cell sarcoma (%) and desmoplastic small round cell tumor (DSRCT) (%); all other non-NB tumors will require confirmation of GD expression on cell surface by immunohistochemistry on fresh frozen tissue that will be performed at MSKCC; patients with suspected GD-positive tumors (other than osteosarcoma, spindle cell sarcoma or DSRCT) will have their tumors assessed after obtaining a separate informed consent for this purpose
Patients with tumors located outside the ventricles (basal ganglia, thalamus) are not eligible
Patients with histologically confirmed unresectable or metastatic pancreatic (p)NETs of low or intermediate grade; high-grade tumors or tumors with small cell histology will be excluded (Part )
Patients with histologically or cytologically proven lung or esophageal cancers, thymic or mediastinal germ cell tumors, malignant pleural mesotheliomas, or primary thoracic sarcomas, as well as patients with sarcomas, melanomas, germ cell tumors, or epithelial malignancies metastatic to the lungs, mediastinum, or pleura that have no clinical evidence of active disease (NED) or minimal residual disease (MRD) not readily accessible by non-invasive biopsy or resection/radiation following standard therapy
Tumors must have a Ki- index greater than % and/or >  mitotic figures/ high-power fields
Subjects with resected primary tumors who have documented metastases are eligible
Patients with primary CNS tumors are not eligible
Patients with carcinoid tumors
Selected tumors with rhabdoid features
Other INI-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval
Cohort  - MRT/RTK/selected tumors with rhabdoid features
Cohort  - INI-negative tumors:
Other INI-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval
For subjects with INI-negative tumors only - have the following test results available:
Morphology and immunophenotypic panel consistent with INI-negative tumors, and
Tumors that are amenable to serial biopsy
Carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors.
Patients with bilateral renal tumors are eligible provided both tumors have undergone full surgical resection and at least one of the tumors meets all eligibility criteria; patients must plan to start study drug within  days after the date of the resection of the first tumor
Inaccessible tumors or for whom biopsy is contraindicated
Patients with non-adenocarcinomas, adenosquamous carcinomas, islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas; patients with tumors that are largely IPMN with a minimal or minor component of invasive carcinoma are not eligible; patients with acinar carcinomas are not eligible; patients with IPMNs that contain some secondary (minor) foci of adenocarcinoma are also not eligible
Individuals with inaccessible tumors or for whom biopsy is contraindicated
Documented IDHR-mutant tumors
Metastatic or inoperable solid tumors* (except gastrointestinal tumors or tumors that originated or metastasized to the liver) for which no standard treatment exists, or have progressed or recurred following prior therapy.
Gastrointestinal tumors, tumors that have originated or metastasized to the liver, or other tumors known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
Screening for Rb applies to all patients with available tissue except for patients diagnosed with DIPG and bi-thalamic tumors.
Bi-thalamic tumors, biopsied and noted to have intact RB. Bi-thalamic tumors that are not biopsied will be eligible to enroll on the DIPG/bi-thalamic non-biopsied arm.
Patients with primary brain tumors are excluded; patients with metastatic brain tumors may be enrolled
No radiographic evidence of cavitary or necrotic tumors
Any patients with infratentorial tumors
Periampullary tumors
Locally advanced tumors at diagnosis (T), including tumors fixed to the chest wall, peau dorange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid)
Patients must have a histologically confirmed solid tumor malignancy at either original diagnosis or relapse for which no curative therapy exists, and which has either recurred or progressed after at least one prior systemic therapy; patients with primary brain tumors, or those with brain metastases at time of potential enrollment, are excluded; additionally, patients with gastrointestinal stomal tumors (GIST), alveolar soft part sarcoma, or dermatofibrosarcoma protuberans are excluded
Eyes with tumors that are amenable to local therapy with laser or cryotherapy without threat to vision
For subjects enrolled for a major deformity or significantly disfiguring tumor, eligible tumors will be limited to tumors of the head & neck or those on other areas of the body that are unable to be concealed by standard garments; in order to enroll a plexiform neurofibroma for these indications, the study chair or co-chair must be contacted to review subject eligibility prior to enrollment
other solid tumors (all comers) for which there is no standard systemic therapy and there is a rationale for use of pexidartinib at the Investigator's discretion
Phase : All solid tumors (measurable or evaluable disease), including primary central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas
Technically resectable, single tumors of any size, tumors with satellite nodules within  cm of the primary tumor that are resectable; limited and resectable multi- focal disease (less than  tumors technically resectable)
VS or meningioma surgery determined clinically necessary by the treating physician; similar cerebellopontine (CP) angle schwannomas, such as facial nerve schwannomas and collision tumors, i.e. tumors arising from multiple cranial nerves, are eligible
Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau dorange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)
T tumors
Patients with nervous system tumors associated with NF (e.g., schwannomas, meningiomas, ependymomas, or gliomas) will not be excluded from this clinical trial unless (in the opinion of the investigator) these tumors are growing and are likely to require treatment during the clinical trial
Patients with bladder tumors which are endoscopically resectable by surgeons judgment with only one trip into the operating room
Patients with centrally-located pulmonary or mediastinal primary tumors or metastases adjacent to or invading large blood vessels
Tumors poorly visualized by x-ray mammography or ultrasound imaging
Cavitary tumors or tumors invading or abutting large blood vessels.
Tumors must be supratentorially located
Patients with T tumors on both cords (Tb)
Patients with Tb-T true larynx tumors
Patients with primary supraglottic tumors that involve the true larynx
Detectable AR-V from circulating tumors (CTCs)
Radiographic evidence of cavitary or necrotic tumors
Based on the results of the mutation test, lymphoma subjects may be enrolled in one of four cohorts: GCB-DLBCL EZH mutant cohort: Tumors must contain one, or more, of the following EZH activating mutations: YF; YN; YS; YH; YC; AG; and/or AV. GCB-DLBCL EZH wild type cohort: Tumors that do not contain one of the above mutations; Subjects with tumors harboring EZH mutations other than the seven outlined above will be enrolled in the EZH wild type cohort. tFL EZH mutant cohort: Tumors must contain one, or more, of the following EZH activating mutations: YF; YN; YS; YH; YC; AG; and/or AV. tFL EZH wild type cohort: Tumors that do not contain one of the above mutations; Subjects with tumors harboring EZH mutations other than the seven outlined above will be enrolled in the EZH wild type cohort
Patients who have benign or malignant soft tissue tumors of the extremities, flanks, pelvis, or shoulders that require surgical intervention
Histologically confirmed solid tumors, including primary brain tumors; in subjects with brain stem or optic gliomas the requirement for histological confirmation may be waived
Tumors clinically staged as unresectable disease
Patients who do not have pure uterine sarcomas (i.e., no mixed malignant Mullerian tumors).
Patients must have a metastatic or unresectable locally advanced malignant solid tumor, histologically confirmed by the Laboratory of Pathology, National Cancer Institute (NCI); in the case of chordoma, unresectable, locally recurrent, or metastatic tumors are acceptable for enrollment, given that this represents incurable disease; efforts will be made, as much as possible, to enroll patients with tumor types with known increased expression of brachyury (such as lung, breast, ovarian, prostate, colorectal, pancreatic, or chordoma; other tumors may be included as data on the level of brachyury in those tumors becomes available)
Primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary tumors
Patients must have histologically or cytologically confirmed low or intermediate grade pancreatic NET; patients with neuroendocrine tumors associated with multiple endocrine neoplasia type  (MEN) syndrome will be eligible
Tumors of the lips, sinuses, salivary glands or nasopharynx.
Cavitary tumors or tumors invading or abutting large blood vessels
Has advanced gastrointestinal tumors refractory to at least  chemotherapy
Patients whose tumors score + by conventional IHC, are non-amplified by FISH testing, and whose tumors score > or = . by HERmark testing, are eligible for the study.
Histologically confirmed solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, primary brain tumors, NF- associated PF and LCH. In subjects with brain stem gliomas the requirement for histological confirmation can be waived if a biopsy was not performed. For plexiform neurofibromas, histologic confirmation of tumor is not necessary in the presence of consistent clinical and radiological findings, but should be considered if malignant degeneration of a PN is clinically suspected.
Recurrent or refractory BRAFV mutant LGG or LCH tumors
NET and GIST tumors must be unresectable
tumors must be measurable
Radiographic evidence of cavitary or necrotic tumors
Have any other functional tumors if they have familial Multiple Endocrine Neoplasia Syndrome  or  (MEN  or MEN ).
Pathologically confirmed metastatic unresectable well differentiated (low grade and intermediate grade) neuroendocrine tumors (Ki- < % and mitotic rate <  per  high power field) that demonstrate progressive disease (by serial computed tomography [CT] or magnetic resonance imaging [MRI] scans) in past  months including\r\n* Carcinoid tumors originating anywhere in the body including the gastrointestinal (GI) tract or bronchial tree or thymus\r\n* Pancreatic neuroendocrine tumors (including functional and non-functional islet cell, insulinomas and glucagonomas)\r\n* Pheochromocytomas\r\n* Gastrinomas (Zollinger-Ellison syndrome)\r\n* Multiple endocrine neoplasia (MEN type I/II),\r\n* Adrenal carcinomas with NET markers by immunohistochemistry (IHC) or serum\r\n* Somatostatinoma\r\n* VIPoma (vasoactive intestinal peptide)\r\n* Merkel cell tumors\r\n* Medullary thyroid carcinoma\r\n* Neuroendocrine tumors of unknown primary site
Patients with central tumors within the proximal tree or touching the mediastinal pleura
Patients with infra-tentorial tumors are not eligible
Tumors that are Her positive are eligible
TanyN+M or T-N any M tumors
Patients with brain tumors
Primary brain tumors
Elective craniotomy for supratentorial brain tumors
Undergoing elective craniotomy for supratentorial tumors
Infratentorial tumors
Patients will receive repeated cycles of identical chemotherapy that will likely result in grades III-IV hematological toxicity; patients will be treated outside of Childrens Oncology Group (COG) protocols with specific requirements for schedule of G-CSF administration; the following categories of patients treated at Childrens Hospital of Michigan are eligible for this study:\r\n* Patients with brain tumors treated according to modified Head Start II protocol with vincristine, etoposide, cyclophosphamide, and cisplatin (OPEC) chemotherapy;\r\n* Patients with recurrent Hodgkin lymphoma treated with ICE (ifosfamide, carboplatin, etoposide) chemotherapy;\r\n* Patients with recurrent solid tumors including sarcomas, Wilms tumor, neuroblastomas, or brain tumors treated with high dose ICE or ICT (ifosfamide, carboplatin, topotecan) chemotherapy
Diagnostic categories\r\n* Sarcoma (soft tissue and bone)\r\n* Kidney tumors\r\n* Brain tumors\r\n* Other solid tumors (gonadal and germ cell tumors, retinoblastoma, neuroblastoma, and miscellaneous tumors)\r\n* Hodgkin lymphoma
Absence of tumors:\r\n* Patients must undergo thorough physical examination of the leg undergoing surgery; if physical exam is equivocal for presence of tumors, then a normal magnetic resonance imaging (MRI) of the lower extremity will be required before eligibility is met\r\n* If there is evidence of plexiform neurofibroma or nodular neurofibroma of >  cm diameter on the ipsilateral leg, then they are ineligible for the study
Benign tumors, neuroendocrine tumors, soft tissue tumors based on preoperative work-up or intraoperative findings
Tumors must be suitable for cryoablation
Diagnosis of primary brain tumors
Patients with primary tumors located above the carina
Intracoelomic primary tumors or tumors expected to drain to an intracoelomic SLN
Patient with more than  tumors treated with any percutaneous ablation
Adults with intraocular tumors (melanoma, metastasis, retinal tumors) who are going to undergo enucleation diagnosed in the Emory Eye Center Ocular Oncology Service; patients will be assessed by a cardiologist or cardiology fellows
Known or suspected somatostatin receptor positive neuroendocrine tumors (NETs) (e.g. carcinoid, pancreatic neuroendocrine tumors, and pheochromocytoma); supporting evidence may include magnetic resonance imaging (MRI), CT, biochemical markers, and or pathology report
Patients with primary or metastatic tumors in the lungs, liver, or pancreas
Patients with Tb tumors or T tumors >  cm or patients with tumors involving the central chest/structures of the mediastinum
Patients presenting with brain tumors will be eligible for this study
Prior craniotomy for resection of deep seated tumors in thalamus and brain stem
A known other currently active malignancy; (benign tumors and benign polyps, basal cell carcinomas of skin, superficial papillary bladder tumors, and pre-invasive carcinoma of the cervix are permitted)
Tumor tissue or blood collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing complete disease response (CR)
Tumors near critical structures such as those located near or in the brain or spine. This assessment will be determined by the treating clinician.
Germ cell tumors (GCTs).
Tumors located in the central chest or other location where bleeding is associated with high morbidity
